Lupin Limited, headquartered in Mumbai, India has successfully positioned itself as a Transnational Pharmaceutical Company, with a wide global footprint. The Company develops and markets a wide range of quality, affordable generic and branded formulations and APIs in multiple markets across the world.

Business Mix
The Company has gained recognition as the world’s largest manufacturer of Tuberculosis drugs. Over the years, the Company has moved up the value chain and has not only mastered the business of certain intermediates and APIs, but has also leveraged its strengths to build a formidable formulations business. It has a significant presence in Cephalosporins, Cardiovasculars (prils and statins), Diabetology, Asthama and NSAIDs therapy segments. Over the last four years, the Company’s business mix has improved with close to 70% of its revenues coming from formulations and 30% from APIs.

Global Footprint
The Company has a wide onshore and offshore presence with its products available in close to 70 countries. In terms of overall revenues, the overseas business constitutes close to 55%, while the balance comes from the domestic market. Lupin has retained a stronghold in India growing ahead of the industry and has achieved a formidable position in many segments leveraging its sound marketing prowess and a wide product basket.

The US is Lupin’s largest market overseas where it has developed a robust branded and generic business. Over a period of four years, Lupin has developed a business of US$ 200 mn in the US and has been recognized as one of the fastest growing Companies in this market. The Company aspires to replicate this success in other Advanced Markets such as Europe, Japan and Australia.

During 2007, Lupin fast tracked its growth trajectory through two acquisitions. While the acquisition of Kyowa positioned the Company amongst the top ten generic pharma Companies in Japan; another acquisition in India provided it a springboard to leap ahead in the CRAMS space.

Manufacturing
Lupin’s manufacturing facilities, spread across India, play a critical role in enabling the Company realize its global aspirations, benchmarked to International standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, TGA Australia, WHO, and MCC South Africa. The Company has leveraged its strong vertical integration in building a global pharmaceutical powerhouse.

Research
The Company’s intellectual pool of over 400 scientists is constantly engaged in path breaking research. Its focus on drug discovery and advanced drug delivery systems research has resulted in significant progress in its Novel Drug Discovery & Development program and development of platform technologies that are being used to develop value-added generic pharmaceuticals. Company’s strong focus on creating Intellectual Property (IP) assets has resulted in generating revenue streams through IP. The Company’s overall research prowess enables it to master cutting edge science and technology.

Financials
Currently positioned amongst the top five pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders. For the financial year ended March 2008, Lupin's Revenues and Profit after Tax were Rs.27,730 mn (US$ 694 mn) and Rs.4,083 mn (US$ 102 mn) respectively. The Company reported a 34 % rise in revenues while the Net profit increased by 32%.

The company incurred R& D expenditure of Rs 1546 mn, which is 6 % of its gross sales.

Going Forward
Lupin is poised to capitalize the opportunities that are set to unfurl in the global pharmaceutical space and establish itself as an innovation led transnational pharmaceutical company.